Mandate

Vinge advises Carl Lamm in connection with recapitalization offer and listing

May 13, 2008

Vinge advises Carl Lamm Holding AB (publ) in connection with the recapitalization offer regarding Carl Lamm AB (publ) and the listing of Carl Lamm Holding. On 6 May 2008, Carl Lamm Holding announced a public offer to acquire all shares in Carl Lamm. The consideration in the offer is a combination of cash and shares in Carl Lamm Holding. The total value of the offer amounts to approximately SEK 592 million. Carl Lamm Holding is expected to be listed on OMX Nordic Exchange Stockholm on or about 26 June 2008.


Jan Lombach, Mattias Friberg and Emil Hedberg are coordinating the work and are proving corporate and capital markets advice. Mattias Schömer, Maria Schultzberg, Maria Doeser and Johan Bocander are providing tax advice. Mikael Ståhl, Paula Röttorp and Christina O Rosén are providing advice regarding the financing.


The IT company Carl Lamm operates in the document and information management industry and has a nationwide organization with operations in 25 strategic locations in Sweden, offering solutions for customers’ various IT environments. Carl Lamm is the exclusive Swedish distributor for Ricoh products, Philips voice management products, Francotyp-Postalia postage meter systems and distributor for Samsung multifunctional products. Furthermore, the company is a HP Preferred Partner and a Microsoft Gold Partner. Carl Lamm is listed on OMX Nordic Exchange Stockholm.

Related

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024

Vinge advises Triton in connection with the divestment of Norstat to Nalka Invest

Vinge advises Triton Smaller Mid-Cap Fund I (“Triton”) in connection with the divestment of Norstat, a leading data collector for market research, to Nalka Invest.
April 12, 2024